NASDAQ | ETF
Top 13 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 8.98% |
| UNH | UnitedHealth Group Incorporated | Healthcare | Healthcare Plans | 7.23% |
| NOVO-B | Novo Nordisk A/S | Healthcare | Biotechnology | 5.37% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 5% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.59% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 4.57% |
| DHR | Danaher Corporation | Healthcare | Diagnostics & Research | 3.38% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 3.26% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 3.02% |
| CI | Cigna Corp | Healthcare | Healthcare Plans | 2.85% |
| SYK | Stryker Corporation | Healthcare | Medical Devices | 2.8% |
| SAN | Sanofi SA | Healthcare | Drug Manufacturers - General | 2.78% |
| CNC | Centene Corp | Healthcare | Healthcare Plans | 2.74% |
The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.